Sale!

Human Papillomavirus HPV Genotype Test

Original price was: $250.Current price is: $188.

-25%

The Human Papillomavirus HPV Genotype Test is a sophisticated DNA-based screening that identifies specific high-risk HPV strains associated with cervical cancer development. Using advanced Sanger Sequencing technology, this test provides precise genotype information for 14 high-risk HPV types, including HPV 16 and 18, which are responsible for over 70% of cervical cancer cases. This comprehensive screening is essential for women aged 21-65 as part of routine cervical health monitoring. The test requires a cervical swab sample and delivers results within 4-5 days. Early detection through HPV genotyping allows for timely intervention and significantly reduces cervical cancer risk. The test is available for $188 USD (discounted from $250) at our nationwide locations.

Clinically Validated & Lab Certified

  • ISO-Accredited Laboratory, Ensuring Highest Standards
  • Trusted by Hospitals & Patients —Accredited Testing with Results
  • Direct Healthcare Provider Support + Comprehensive Reporting
Guaranteed Safe Checkout

Human Papillomavirus HPV Genotype Test

Comprehensive HPV DNA Testing for Cervical Health

The Human Papillomavirus HPV Genotype Test represents a breakthrough in cervical cancer prevention and women’s health screening. This advanced molecular diagnostic test utilizes cutting-edge Sanger Sequencing technology to identify and differentiate between specific high-risk HPV strains that are clinically significant for cervical cancer development. Unlike traditional Pap smears that detect cellular changes, HPV genotyping directly identifies the presence of cancer-causing virus types, providing crucial information for personalized risk assessment and management strategies.

What Does the HPV Genotype Test Detect?

Our comprehensive HPV Genotype Test screens for 14 high-risk HPV types that are medically recognized as having strong associations with cervical cancer development:

  • HPV 16 and 18 – Responsible for approximately 70% of all cervical cancer cases
  • HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 – Additional high-risk types with varying cancer potential

The test employs sophisticated DNA sequencing technology to provide precise genotype information, enabling healthcare providers to determine exactly which HPV types are present and assess individual cancer risk with unprecedented accuracy.

Who Should Consider HPV Genotype Testing?

This advanced screening is recommended for:

  • Women aged 21-65 as part of routine cervical cancer screening
  • Patients with abnormal Pap smear results for further risk stratification
  • Women aged 30+ for primary HPV testing every 5 years
  • Individuals with persistent HPV infections requiring genotype monitoring
  • Patients with compromised immune systems who may need more frequent screening
  • Women seeking comprehensive cervical health assessment beyond standard Pap testing

Key Benefits of HPV Genotype Testing

  • Early Cancer Detection – Identifies high-risk HPV types before cellular changes occur
  • Personalized Risk Assessment – Differentiates between HPV 16/18 and other high-risk types
  • Improved Screening Accuracy – More sensitive than Pap testing alone for detecting precancerous conditions
  • Longer Screening Intervals – Negative HPV results may allow for extended screening periods
  • Better Treatment Planning – Specific genotype information guides appropriate follow-up care
  • Peace of Mind – Comprehensive testing provides reassurance about cervical health status

Understanding Your Test Results

Your HPV Genotype Test results will fall into one of these categories:

  • Negative for High-Risk HPV – No cancer-causing HPV types detected. Routine screening recommended based on age and guidelines.
  • Positive for HPV 16/18 – Highest risk types detected. Immediate colposcopy and closer monitoring typically recommended.
  • Positive for Other High-Risk HPV – Non-16/18 high-risk types detected. Follow-up testing and monitoring based on individual risk factors.
  • Multiple HPV Types Detected – Co-infection with multiple high-risk types may indicate increased cancer risk requiring specialized management.

Always discuss your results with your healthcare provider who can interpret them in the context of your medical history, age, and previous screening results.

Test Pricing and Availability

Test Name Regular Price Discount Price
Human Papillomavirus HPV Genotype Test $250 USD $188 USD

Nationwide Testing Availability

We have conveniently located testing centers across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our state-of-the-art facilities ensure consistent, high-quality testing standards nationwide.

Important Pre-Test Information

The Human Papillomavirus HPV Genotype Test requires a cervical swab sample collected by a healthcare professional. Please note:

  • A doctor’s prescription is required for this test
  • Prescription requirements do not apply for surgical cases, pregnancy, or international travel planning
  • Results are typically available within 4-5 business days
  • Sample is collected in a sterile container provided by our facility
  • No special preparation is needed before sample collection

Take Control of Your Cervical Health Today

Don’t wait to get the comprehensive cervical health information you need. Early detection through HPV genotyping can significantly reduce your risk of developing cervical cancer. Our advanced DNA testing technology provides the most accurate HPV strain identification available.

Call or WhatsApp us now at +1(267) 388-9828 to schedule your HPV Genotype Test appointment. Our knowledgeable staff is ready to answer your questions and help you book your test at a location convenient for you.

Invest in your health with the most advanced HPV screening technology available. Book your test today and take the first step toward comprehensive cervical cancer prevention.